This transmittal amends guidance provided in Transmittal #22-18 COVID-19 Monoclonal Antibody Infusions Update issued April 25, 2022. This update reflects updated coverage per the latest guidance by the FDA for the non-authorization of sotrovimab by GSK.

This transmittal provides notice of coverage and reimbursement for Monoclonal Antibody infusions in the professional fee schedule for fee-for-service providers that bill HCPCS and CPT codes on CMS-1500 claim forms, and for providers enrolled in Medicaid Managed Care Organization (MCO) networks.